Literature DB >> 24932809

Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells.

Pedro Gonzalez-Menendez1, David Hevia, Aida Rodriguez-Garcia, Juan C Mayo, Rosa M Sainz.   

Abstract

Cancer cells show different metabolic requirements from normal cells. In prostate cancer, particularly, glycolytic metabolism differs in androgen-responsive and nonresponsive cells. In addition, some natural compounds with antiproliferative activities are able to modify glucose entry into cells by either modulating glucose transporter (GLUT) expression or by altering glucose binding. The aim of this work was to study the regulation of some GLUTs (GLUT1 and GLUT4) in both androgen-sensitive (LNCaP) and -insensitive (PC-3) prostate cancer cells by 4 structurally different flavonoids (ie, genistein, phloretin, apigenin, and daidzein). Glucose uptake was measured using nonradiolabeled 2-deoxyglucose. The evaluation of protein levels as well as subcellular distribution of GLUT1/4 were analyzed by Western blot and immunocytochemistry, respectively. Androgen-insensitive LNCaP-R and androgen-sensitive PC-3-AR cells were used to study the effect of androgen signaling. Additionally, a docking simulation was employed to compare interactions between flavonoids and XylE, a bacterial homolog of GLUT1 to -4. Results show for the first time the presence of functionally relevant GLUT4 in prostate cancer cells. Furthermore, differences in GLUT1 and GLUT4 levels and glucose uptake were found, without differences on subcellular distribution, after incubation with flavonoids. Docking simulation showed that all compounds interact with the same location of transporters. More importantly, differences between androgen-sensitive and -insensitive prostate cancer cells were found in both GLUT protein levels and glucose uptake. Thus, phenotypic characteristics of prostate cancer cells are responsible for the different effects of these flavonoids in glucose uptake and in GLUT expression rather than their structural differences, with the most effective in reducing cell growth being the highest in modifying glucose uptake and GLUT levels.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24932809     DOI: 10.1210/en.2014-1260

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  20 in total

1.  Anticancer agents interacting with membrane glucose transporters.

Authors:  C Granchi; S Fortunato; F Minutolo
Journal:  Medchemcomm       Date:  2016-07-08       Impact factor: 3.597

2.  GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling.

Authors:  Mark A White; Efrosini Tsouko; Chenchu Lin; Kimal Rajapakshe; Jeffrey M Spencer; Sandi R Wilkenfeld; Sheiva S Vakili; Thomas L Pulliam; Dominik Awad; Fotis Nikolos; Rajasekhara Reddy Katreddy; Benny Abraham Kaipparettu; Arun Sreekumar; Xiaoliu Zhang; Edwin Cheung; Cristian Coarfa; Daniel E Frigo
Journal:  Endocr Relat Cancer       Date:  2018-02-05       Impact factor: 5.678

Review 3.  Nutrition, dietary interventions and prostate cancer: the latest evidence.

Authors:  Pao-Hwa Lin; William Aronson; Stephen J Freedland
Journal:  BMC Med       Date:  2015-01-08       Impact factor: 8.775

4.  The Impact of Soy Isoflavones on MCF-7 and MDA-MB-231 Breast Cancer Cells Using a Global Metabolomic Approach.

Authors:  Alina Uifălean; Stefanie Schneider; Philipp Gierok; Corina Ionescu; Cristina Adela Iuga; Michael Lalk
Journal:  Int J Mol Sci       Date:  2016-08-31       Impact factor: 5.923

5.  Melatonin Decreases Glucose Metabolism in Prostate Cancer Cells: A 13C Stable Isotope-Resolved Metabolomic Study.

Authors:  David Hevia; Pedro Gonzalez-Menendez; Mario Fernandez-Fernandez; Sergio Cueto; Pablo Rodriguez-Gonzalez; Jose I Garcia-Alonso; Juan C Mayo; Rosa M Sainz
Journal:  Int J Mol Sci       Date:  2017-07-26       Impact factor: 5.923

6.  GLUT1 protects prostate cancer cells from glucose deprivation-induced oxidative stress.

Authors:  Pedro Gonzalez-Menendez; David Hevia; Rebeca Alonso-Arias; Alejandro Alvarez-Artime; Aida Rodriguez-Garcia; Sandrina Kinet; Ivan Gonzalez-Pola; Naomi Taylor; Juan C Mayo; Rosa M Sainz
Journal:  Redox Biol       Date:  2018-04-12       Impact factor: 11.799

7.  Drug-target-disease network analysis of gene-phenotype connectivity for genistein in ovarian cancer.

Authors:  Chen Zhang; Fan Yang; Suiqin Ni; Wenbing Teng; Yingxia Ning
Journal:  Onco Targets Ther       Date:  2018-12-10       Impact factor: 4.147

8.  Construction and analysis of protein-protein interaction networks based on proteomics data of prostate cancer.

Authors:  Chen Chen; Hong Shen; Li-Guo Zhang; Jian Liu; Xiao-Ge Cao; An-Liang Yao; Shao-San Kang; Wei-Xing Gao; Hui Han; Feng-Hong Cao; Zhi-Guo Li
Journal:  Int J Mol Med       Date:  2016-04-26       Impact factor: 4.101

Review 9.  Evidence to Support the Anti-Cancer Effect of Olive Leaf Extract and Future Directions.

Authors:  Anna Boss; Karen S Bishop; Gareth Marlow; Matthew P G Barnett; Lynnette R Ferguson
Journal:  Nutrients       Date:  2016-08-19       Impact factor: 5.717

10.  Acute metabolic actions of the major polyphenols in chamomile: an in vitro mechanistic study on their potential to attenuate postprandial hyperglycaemia.

Authors:  Jose A Villa-Rodriguez; Asimina Kerimi; Laszlo Abranko; Sarka Tumova; Lauren Ford; Richard S Blackburn; Christopher Rayner; Gary Williamson
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.